All In Biotech

Drug Trial Radar · NCT06575153

Phase 1 Study of ART5803 in Healthy Participants

A Phase 1, Randomized, Double-blind, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ART5803 Compared With Placebo in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Sep 19, 2024

Primary completion

Sep 11, 2025

Study completion Oct 31, 2025

Sponsor

Lead sponsor
Arialys TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is a Phase 1, single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, pharmacokinetics (PK), and immunogenicity of ART5803 compared with placebo in healthy adult participants

Conditions

  • Autoimmune Encephalitis

Interventions

  • ART5803Drug

    A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety will be assessed by the incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: 12 weeks
  2. Safety will be assessed by clinically significant changes in physical and neurological examination findingsTime frame: 12 weeks
  3. Safety by assessed by clinically significant changes in vital signsTime frame: 12 weeks
  4. Safety by assessed by clinically significant changes in clinical laboratory outcomesTime frame: 12 weeks
  5. Safety by assessed by clinically significant changes in 12-lead ECG findingsTime frame: 12 weeks
  6. Safety by assessed by clinically significant changes in concomitant medicationsTime frame: 12 weeks
  7. Safety by assessed by clinically significant changes in presence of anti-drug antibodies (ADAs)Time frame: 12 weeks
  8. Safety will be assessed by incidence of dose-limiting toxicity (DLTs)Time frame: 12 weeks
  9. Safety will be assessed by change in suicidal tendency measured by Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Pty Ltd

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.